NUMI.V

VANCOUVER, BC, Dec. 13, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, congratulates the Multidisciplinary Association of Psychedelics Studies ("MAPS" or "MAPS PBC") for its submission of a new drug a... Read More...

VANCOUVER, BC, Sept. 25, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), is pleased to announce that it has established an at-the-market equity offering program (the "ATM Program") that allows the Company to issue and sell up to C$10,000,000 of common shares in the capital of the Company (the "Common Shares") from tim... Read More...

The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience. Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses,... Read More...

VANCOUVER, BC, June 14, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the appointment of Nikhil Handa as Chief Financial Officer, effective June 15, 2023, following a thorough executi... Read More...

First Numinus Network™ partner enters into agreement Recent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned to provide psychedelic-assisted therapy insurance reimbursement, as a result of recent US insurance payor code approval MDMA-assisted therapy e... Read More...

VANCOUVER, BC, April 14, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new client website at www.numinus.com as part of its branding strategy to align all welln... Read More...

New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy. Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea – one of the first Phase 1 clinical trials that will report on whole Psilocybe mushroom safety. VANCOUVER, BC, Dec. 8, 2022 - Numinus Wellness ... Read More...

 VANCOUVER, BC, Oct. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Cent... Read More...

Clinical program broadens access to ketamine-assisted therapy for an underserved population VANCOUVER, BC, Oct. 28, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the launch of its Ket... Read More...

Psilocybin-containing tea bag offers substitute for whole mushrooms and other solid therapeutics VANCOUVER, B.C, Oct. 5, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its researc... Read More...

Treatment will be offered at the Neurology Centre of Toronto in Forest Hill VANCOUVER, BC, Sept. 19, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its Toronto clinic, the Neurol... Read More...

VANCOUVER, BC, Aug. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte ... Read More...

Approval Marks Numinus' First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials VANCOUVER, BC, May 16, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Health Ca... Read More...

VANCOUVER, BC, May 11, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a fireside chat hosted by Patrick Trucchio, H.... Read More...

Numinus leaders will speak at Catalyst, Psychedelic Therapeutics & From Research to Reality VANCOUVER, BC , May 9, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced participation in th... Read More...

VANCOUVER, BC, March 15, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Maxim Group's 2022 Virtual Growth Conference to be held virtually on March 28-30, 20... Read More...

VANCOUVER, BC, Feb. 28, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held earli... Read More...

Dr. Devon Christie, Dr. Robin Carhart-Harris, Dr. Frederick Barrett and Tura Patterson will discuss "Psychedelic Research: Moving Beyond the Social and Political Stigma" VANCOUVER, BC, Feb. 10, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF) a mental healthcare company advancing innovative treatments and safe, evidence... Read More...

The trial evaluates Numinus' first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its... Read More...

Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, commends Health Canada's leadership for amending th... Read More...

Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients VANCOUVER, BC, Nov. 29, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compo... Read More...

VANCOUVER, BC, Nov. 25, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions that Stacey Wallin, former Chief Strategy Officer, is no longer with t... Read More...

Numinus will manage two new clinics in Montreal and Vancouver to host trials. VANCOUVER, BC, Nov. 10, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has secured two new Canadian psychedelic clinics that will host the Canadian sites of the MAPS Publi... Read More...